Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Michael R Migden"'
Autor:
Matthew G. Fury, Anne Lynn S. Chang, David M. Weinreich, Leonel Hernandez-Aya, Friedegund Meier, Chrysalyne D. Schmults, Israel Lowy, Axel Hauschild, Elizabeth Stankevich, Carola Berking, Deborah J. Wong, Vladimir Jankovic, George D. Yancopoulos, Nikhil I. Khushalani, Danny Rischin, Michael R. Migden, Gregory A. Daniels, Siyu Li, Alexander Guminski, Karl D. Lewis, Dirk Schadendorf, Jocelyn Booth
Publikováno v:
Lancet Oncol
Summary Background Cemiplimab has shown substantial antitumour activity in patients with metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous squamous cell carcinoma have poor prognosis with conventional systemic the
Autor:
Matthew G. Fury, Siyu Li, Medha Sasane, Dirk Schadendorf, Nikhil I. Khushalani, Karl D. Lewis, Vera Mastey, Elizabeth Stankevich, Axel Hauschild, Jocelyn Booth, Michael R. Migden, Anne Lynn S. Chang, Suk Young Yoo, Chieh I. Chen, Leonel Hernandez-Aya, Emmanuel Okoye, Zhen Chen, Chrysalyne D. Schmults, Israel Lowy, Alexander Guminski, Brett G.M. Hughes, Danny Rischin, Alesha A. Thai, Annette M. Lim
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
BackgroundTo provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration of response (DOR) and impact on quality of life (QoL).Method
Autor:
Michael R. Migden, David I. Rosenthal, Randal S. Weber, Priyadharsini Nagarajan, Elsa R. Flores, Amy C. Moreno, Jobran Mansour, Neil D. Gross, Bonnie S. Glisson, Deborah A. Silverman, Ryan P. Goepfert, Frederico O. Gleber-Netto, Goujun Li, Michael K. Wong, Anshu Khanna, Adel K. El-Naggar, Jeffrey N. Myers, Renata Ferrarotto, Erez N. Baruch, Moran Amit, Samantha Tam, Kenneth Y. Tsai, Chuan Liu, Mohamed Aashiq
Publikováno v:
Cancer
Background The survival benefit of elective neck dissection (END) for patients with cutaneous squamous cell carcinoma (cSCC) of the head and neck and no evidence of regional metastasis (cN0) has never been reported. The aim of this study was to deter
Autor:
Michael R. Migden, Axel Hauschild, Ralf Gutzmer, Suk Young Yoo, Nathalie Fiaschi, Matthew G. Fury, Jens Ulrich, Karl D. Lewis, Reinhard Dummer, Susana Puig, Anne Lynn S. Chang, Vincenzo De Giorgi, Claas Ulrich, Nicole Basset-Seguin, Almudena Fernandez Orland, Lisa Licitra, Sorilla Prey, Emmanuel Okoye, David M. Weinreich, Ketty Peris, Israel Lowy, Ebony Coates, Stéphane Dalle, Timothy Bowler, Martin Kaatz, George D. Yancopoulos, Caroline Robert, Frank Seebach, Siyu Li, Zeynep Eroglu, Vladimir Jankovic, Carmen Loquai, Oliver Bechter, Kosalai Kal Mohan, Gavin Thurston, Aleksandar Sekulic, Ioannis D. Bassukas, Alexander J. Stratigos
Publikováno v:
The Lancet. Oncology. 22(6)
Summary Background Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneou
Autor:
Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
BMC Cancer
BMC Cancer
In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic b
Autor:
R. Ferrarotto, Jason M. Johnson, Randal S. Weber, Diana Bell, M. Wong, Neil D. Gross, J.N. Myers, Bonnie S. Glisson, Bita Esmaeli, Ying Yuan, Priyadharsini Nagarajan, Michael R. Migden, David I. Rosenthal, Adel K. El-Naggar, Jennifer A. Wargo
Publikováno v:
Annals of Oncology. 30:v910
Background Cutaneous squamous cell carcinoma (CSCC) harbors a high tumor mutation burden (TMB) due to ultraviolet light-mediated DNA damage, and are highly immune-responsive. Cemiplimab, a monoclonal antibody directed against programmed death 1 (PD-1
Autor:
Ralf Gutzmer, Tingting Yi, Alexander Guminski, Hans Joachim Schulze, Alexander J. Stratigos, Carmen Loquai, Patrick Combemale, Anne Lynn S. Chang, R. Herd, Ragini R. Kudchadkar, Ruth Plummer, Dalila Sellami, Frank Cornelis, Luc Dirix, Michael R. Migden, Reinhard Dummer, Sven Gogov, Karl D. Lewis, John T. Lear, Celine Pallaud, Manisha Mone, Martin Kaatz, Uwe Trefzer
Summary Background Patients with advanced basal cell carcinoma have limited treatment options. Hedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a068ac7f39ea8f9f41d63de9159e17b
https://doi.org/10.5167/uzh-113018
https://doi.org/10.5167/uzh-113018
Autor:
Josina C. Reddy, Anne Lynn S. Chang, Michael R. Migden, Charles M. Rudin, John D. Hainsworth, Howard Mackey, Anthony E. Oro, Karl D. Lewis, Philip Friedlander, Axel Hauschild, Sarah T. Arron, Robert L. Yauch, Richard A. Graham, Jennifer A. Low, Simon Yoo, Luc Dirix, James A. Solomon, Aleksandar Sekulic, Ellen S. Marmur
Publikováno v:
The New England journal of medicine. 366(23)
Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell carcinoma. Although most basal-cell carcinomas are treated surgically, no effective therapy exists for locally advanced or metastatic basal-cell carcinoma. A phase 1 s
Autor:
H.-J. Schulze, R. Herd, Carmen Loquai, Frank Cornelis, Ragini R. Kudchadkar, Karl D. Lewis, Martin Kaatz, Dalila Sellami, Reinhard Dummer, Anne Lynn S. Chang, Patrick Combemale, Alexander Guminski, John T. Lear, Ralf Gutzmer, Tingting Yi, Luc Dirix, Uwe Trefzer, Ruth Plummer, Michael R. Migden, Alexandros Stratigos
Publikováno v:
Annals of Oncology. 25:v1
Aim: The BOLT phase 2 study, comparing 2 doses of sonidegib, a hedgehog pathway inhibitor (HhPI), in pts with advanced BCC (aBCC; NCT01327053), met its primary endpoint of objective response rate ≥30% in both arms in analyses of data collected up t
Autor:
Simon Yoo, Axel Hauschild, Luc Dirix, Anthony E. Oro, Jeannie Hou, Karl D. Lewis, John D. Hainsworth, Aleksandar Sekulic, Huibin Yue, Michael R. Migden
Publikováno v:
Annals of Oncology. 23:ix362
Background Vismodegib (Erivedge™, GDC-0449) is a first-in-class small-molecule inhibitor of the Hedgehog signaling pathway, which is implicated in the pathogenesis of BCC. ERIVANCE BCC is the pivotal trial of vismodegib for treatment of locally adv